Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

two-drug regime

- PMLiVE

Research in HIV therapies

The global community has made significant strides forward in its mission to eradicate the HIV epidemic

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

FDA refuses to back Gilead’s two HIV drugs

Agency questions quality of testing procedures for elvitegravir and cobicistat

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

- PMLiVE

Gilead recalls Vistide due to foreign particles

Affected batch of AIDS symptom treatment sold in the US, Europe and Canada

- PMLiVE

Anker Lundemose appointed CEO of Bionor Pharma

Will lead efforts to develop and commercialise HIV vaccines

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Sexual health apps fail to attract smartphone users

HIV and STD apps not fulfilling their potential to assist with prevention and care

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links